Bicycle Therapeutics (BCYC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ami Fadia from Needham reiterated a Buy rating on the stock and has a $30.00 price target.
Ami Fadia’s rating is based on the belief that Bicycle Therapeutics’ stock is currently undervalued, especially considering its competitive position in the metastatic urothelial cancer (mUC) market. The company’s innovative Bicycle platform, which has the potential to advance radionuclide therapy, further supports this positive outlook.
Key factors influencing this Buy rating include anticipated data updates from their pipeline, such as BRC imaging data targeting M1-MMP and EphA2 expected in mid and second half of 2025, respectively. Additionally, upcoming dose selection results from the Duravelo-2 study and potential updates on other assets like BT5528 and BT7480 contribute to the optimism surrounding the company’s future prospects.
According to TipRanks, Fadia is a 4-star analyst with an average return of 3.2% and a 45.64% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Merus, and Bicycle Therapeutics.
In another report released today, Barclays also maintained a Buy rating on the stock with a $40.00 price target.